Author

Dan Cai

Army Medical University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Chi YangiD· 1 shared Dong FangiD· 1 shared E GuojiiD· 1 shared Erlong ZhangiD· 1 shared Fan Wang· 1 shared Gang XuiD· 1 shared Guibo LiiD· 1 shared Guo Bai· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Chi YangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Histone H2BK120 ubiquitination modulates PRC1 activity and H2AK119ub deposition on nucleosomes

Ying Yu, Dan Cai, Yuzhu Zhang, Guo Bai, Xinyi Wan, Yu Liu, Fan Wang, Zhuowei Tian, Jianglai Nie, Juan Chen, Han Xue, Ming Lei, Zhiyuan Zhang, Chi Yang, Dong Fang, Jing Huang

The paper reveals how H2BK120ub enhances PRC1 activity and modulates H2AK119ub deposition, linking active and repressive histone modifications in gene regulation.

bioRxiv · Feb 20, 2026 · PreprintMolecular Biology

Hypobaric hypoxia drives citrate cycle reprogramming to suppress tumor progression

Yixing Gao, Xiuju He, E Guoji, Yan Wang, Shirui Huang, Dan Cai, Yumei Deng, Ping Gan, Rui Feng, Qian Liang, Ziyi Tang, Gang Xu, Jian Chen, Hongyu Xue, Qiutong Wang, , Erlong Zhang

This study shows hypobaric hypoxia suppresses tumor progression by reprogramming the citrate cycle and inhibiting the HIF-1 pathway, enhancing antitumor immune response and improving therapy outcomes.

bioRxiv · Aug 15, 2025 · PreprintCancer Biology